New kidney cancer drug shows promise in early trial
NCT ID NCT04846920
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a drug called belzutifan in 29 people with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to check safety and find the right dose. Participants took belzutifan pills daily, and researchers monitored side effects and how the drug moved through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belzutifan (also known as MK-6482, WELIREG™)
What this could lead to
If successful, this could lead to a new treatment option for advanced kidney cancer that has stopped responding to other therapies.
What could go wrong
This is an early Phase 1 trial with only 29 participants, focused on safety. It is too small to prove effectiveness, and side effects may limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center ( Site 1002)
Boston, Massachusetts, 02215, United States
-
University of Michigan ( Site 1006)
Ann Arbor, Michigan, 48109, United States
-
University of Texas MD Anderson Cancer Center-Genitourinary Medical Oncology ( Site 1007)
Houston, Texas, 77030, United States
-
Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1005)
Nashville, Tennessee, 37232, United States